A recent Food and Drug Administration panel on antidepressant use during pregnancy featured several members with longstanding skepticism toward SSRIs. These experts have published work linking the medications to adverse outcomes, signaling potential resistance toward liberal prescribing. Their involvement may influence FDA deliberations over antidepressant recommendations or warnings for pregnant patients, raising questions on the agency's regulatory stance.